<DOC>
	<DOCNO>NCT01165476</DOCNO>
	<brief_summary>The purpose study compare bioavailability single 1mg dose treprostinil diethanolamine sustain release ( SR ) tablet manufacture two independent facility .</brief_summary>
	<brief_title>Comparative Bioavailability Treprostinil Diethanolamine Manufactured Two Independent Facilities</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Subject healthy age 18 55 year , inclusive , Screening Female subject must weigh 45 100 kg , inclusive , BMI 19.029.9 kg/m2 , inclusive Screening . Male subject must weigh 50 120 kg , inclusive , BMI 19.032.0 kg/m2 , inclusive Screening Subject medical history , physical examination , vital sign , ECG clinical laboratory result within normal limit consider clinically significant Investigator Screening Subject clinically relevant abnormality identify screen physical examination , 12lead ECG , laboratory examination . Subject history anaphylaxis , document hypersensitivity reaction , clinically significant idiosyncratic reaction drug Subject clinically significant history neurological , cardiovascular , respiratory , endocrine , hematological , hepatic , renal , gastrointestinal , genitourinary , pulmonary , and/or musculoskeletal disease ; glaucoma ; psychiatric disorder , chronic disease , whether control medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>treprostinil</keyword>
	<keyword>bioavailability</keyword>
	<keyword>bioequivalence</keyword>
</DOC>